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ABSTRACT: The veterinary drug Alfaprostol and prostaglandin 
PGF2 have been synthesized in just 9 steps. The strategy involved 
the conjugate addition of an alkyne to a bicyclic enal, available in 
three steps by a proline-catalyzed aldol reaction of succinaldehyde. 
In the case of Alfaprostol, this resulted in the shortest synthesis 
reported to date. For PGF2 this approach improved our previous 
route by making the 1,4-addition and ozonolysis more operationally 
simple. 
Prostaglandins are involved in many reproductive processes 
in mammals.1 Control of such processes, particularly in 
veterinary medicine, is critical to food production and animal 
welfare.2 For example, prostaglandin PGF2 (1) is known for its 
luteolytic effect (degradation of the corpus luteum) in cattle.3 
This activity is exploited in veterinary practice for the timing of 
insemination and increasing reproductive efficiency. 
Alfaprostol (2) was developed as a more stable and selective 
analogue of PGF2 and is widely used as a potent luteolytic 
agent in cows4 and mares.5 In addition to its application in the 
treatment of glaucoma,6 continued research on PGF2 and its 
analogues (including Alfaprostol) have uncovered a diverse 
array of new biological activity from reduction of adipose 
tissue,7 to the treatment of neuropsychiatric conditions (e.g. 
bipolar disorders).8 These new applications warrant renewed 
and improved syntheses of this important class of compounds.9  
Figure 1. Prostaglandin PGF2 and its synthetic analogue 
Alfaprostol. 
Whilst numerous diverse strategies have been reported for the 
synthesis of PGF2α,
1c strategies towards Alfaprostol have been 
more limited. In fact, they all utilize the Corey lactone as an 
intermediate, only differing in the method for the introduction 
of the alkyne moiety (Scheme 1A). Gandolfi et al. applied a 
sequence of HWE olefination, bromination and double 
dehydrobromination to install the triple bond.10 Monteiro et al. 
used a Seyferth-Gilbert homologation to give the alkyne 
directly, which was converted into a stannane and finally 
coupled with acyl chloride in a Stille coupling.11 Both 
approaches required ca. 17 steps from cyclopentadiene. 
 
Scheme 1. Previous and current strategy towards 
Alfaprostol. 
 
We recently reported a 7-step synthesis of PGF2,
12 and 
similarly short syntheses of Latanoprost and Bimatoprost.13 We 
employed the (L)-proline catalyzed aldol reaction of 
 succinaldehyde as the key step to rapidly assemble the bicyclic 
enal, which was ideally set up to enable the stereoselective 
incorporation of the remaining side chains (Scheme 1B). 
Herein, we report the application of this strategy to an 9-step 
synthesis of Alfaprostol based on the conjugate addition of an 
alkyne to our key enal intermediate. 
1,4-Additions of alkynes to ,-unsaturated aldehydes are 
challenging as alkynes usually form stable complexes with 
copper14 (in fact, they have been used as non-transferable 
groups in mixed organocuprates) and alternative 
organometallics either led to undesired 1,2-addition or no 
reaction. There is just one report of the addition of copper 
acetylides to an enal, which employed iodotrimethylsilane as an 
activator.15 We initially tested this methodology on lactone 313 
with the commercially available alkyne 4 (protected as a silyl 
ether; Scheme 2A).7 Under the reported conditions (at −40 °C), 
we were pleased to find that the addition product 5 was formed, 
after acidic work up, in good yield (48% 1H NMR yield). The 
yield could be increased to 83% (by 1H NMR) by lowering the 
temperature to −78 °C. Crucial for high yields was the quality 
of the TMSI, which had to be stored under the exclusion of 
light, air and moisture.16 
Scheme 2 Model Studies to investigate (a) the 1,4-addition 
to enal 3 and (b) a 1,4 addition/ozonolysis sequence. 
 
Next, we explored whether the conditions were also suitable 
for the 1,4-addition and subsequent ozonolysis with the 
required hemiacetal 6. Thus, the crude reaction mixture 
obtained following 1,4-addition was subjected directly to 
ozonolyis (Scheme 2B). Our standard protocol used in our 
previous prostaglandin synthesis12 involved reaction with 
ozone, followed by flushing the reaction mixture with a stream 
of N2 and subsequent addition of NaBH4 to reduce the ozonide 
and reduce the ketone intermediate. However, under these 
conditions an allenic side product was formed instead of the 
desired alcohol 7. This problem was overcome by reducing the 
ozonide with PPh3 before addition of NaBH4,
17 leading to the 
formation of alcohol 7 in 50% yield over the 2 steps.  
Having established that the conjugate addition to our enal 
substrate was feasible, we moved on to the synthesis of 
Alfaprostol itself. The lower side chain 11 was prepared in 4 
steps starting from 3-cyclohexylpropanoic acid (8; Scheme 3). 
Transformation of acid 8 into the corresponding Weinreb 
amide, and subsequent coupling with ethynylmagnesium 
bromide, gave alkyne 9 in 85% yield over 2 steps. Chiral 
alcohol 10 was obtained by asymmetric CBS-reduction18 in 
87% yield and 97:3 er. Alcohol 10 was protected as a silyl ether 
in 93% yield in the final step.  
Scheme 3 Synthesis of the  side chain. 
 
To complete the synthesis of Alfaprostol (Scheme 4), copper 
acetylide 12 was generated from alkyne 11 and added to enal 6, 
to form intermediate silyl enol ether 13. Subsequent ozonolysis 
and reduction with NaBH4 furnished alcohol 14 in 56% yield 
over the two steps, and with complete stereocontrol over the two 
newly created stereogenic centers at C11 and C12. Double 
deprotection of the silyl and acetal groups under acidic 
conditions gave the hemiacetal intermediate 15, which was used 
without purification in the subsequent Wittig reaction. 
Accordingly, treatment of hemiacetal 15 with the commercially 
available Wittig salt gave Z-alkene 16 with essentially perfect 
selectivity. Finally, esterification19 of acid 16 with methyl 
iodide completed an 9-step synthesis of Alfaprostol (2) with 
complete stereocontrol. 
By synthesizing Alfaprostol, we recognized that the 
conjugate addition of an alkyne to enals 3/6 could also be 
beneficial for the synthesis of PGF2 and other prostaglandin 
analogues, for three reasons. Firstly, our original 1,4-addition to 
the enal required the formation of an organocuprate bearing the 
required vinyl substituent and a non-transferable thiophene 
ligand,12 and its preparation was time consuming, laborious, and 
required the use of t-BuLi. Secondly, we had previously 
required a more functionalized vinyl iodide rather than using 
the commercially available alkyne directly. Thirdly, the 
ozonolysis would become simpler and more reliable due to the 
absence of a second competing double bond, and so timing of 
the addition of ozone would become less critical. We therefore 
revisited the synthesis of PGF2 (Scheme 5). From our initial 
studies, we found that the sequence of 1,4-addition of alkyne 4 
to enal 6 followed by ozonolysis and reduction with sodium 
borohydride gave alcohol 7 in good yield and full stereocontrol, 
over 2 steps (Scheme 2). The alkyne was converted into E-
allylic alcohol 18 by deprotection of the TBDMS group with  
 
 Scheme 4. Synthesis of Alfaprostol 
 
Scheme 5. Synthesis of PGF2
 
TBAF and subsequent Chan-reduction20 with Red-Al. 
Finally, deprotection of the acetal and Wittig olefination gave 
PGF2 1. 
In conclusion, we have developed short routes towards 
Alfaprostol (9 steps longest linear sequence, 12 steps in total) 
and prostaglandin PGF2 (9 steps longest linear sequence, 10 
steps in total). Alfaprostol and PGF2 were synthesized in 23% 
and 18% overall yields from 6, respectively (both were obtained 
in ~3% overall yield from succinaldehyde; the optimization for 
the synthesis of 6 is currently ongoing in our laboratories). In 
comparison to the previous syntheses of Alfaprostol, our key 
enal intermediate is not only accessed in substantially fewer 
steps compared to the Corey lactone, but it is also perfectly set 
up to introduce the alkyne side chain in an efficient, single-step 
fashion. This resulted in the marked step count reduction 
reported here. Furthermore, the conjugate addition of an alkyne 
to the enal intermediate simplifies both the 1,4-addition and 
subsequent ozonolysis significantly. The alkyne functionality 
can be retained or converted into either an alkene or alkane, 
thereby providing access to an even broader array of important 
prostaglandin analogues which are currently used in the clinic. 
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